GLA: Alpha-galactosidase A
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Catalyzes the hydrolysis of glycosphingolipids and participates in their degradation in the lysosome. .
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who Is On It, and How Far Along
Every drug ChEMBL records acting on GLA, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Drug | Furthest stage | Sponsor | Modality | Action | Mechanism | Open trials | Warnings |
|---|---|---|---|---|---|---|---|
| Migalastat | Approved | Amicus Therapeutics US | Small molecule | Stabiliser | Alpha-galactosidase A stabiliser | 6 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 6 in all, from ClinicalTrials.gov.| A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease | Migalastat | Phase 3 | Recruiting | Idorsia Pharmaceuticals Ltd. | 2026-08-21 |
| A Study of Patients With Fabry Disease (US Specific) | Migalastat | — | Recruiting | Amicus Therapeutics | 2025-04-02 |
| A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants | Migalastat | Phase 3 | Recruiting | Amicus Therapeutics | 2025-04-01 |
| A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease | Migalastat | Phase 3 | Active, not recruiting | Sanofi | 2022-03-15 |
| A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding | Migalastat | — | Recruiting | Amicus Therapeutics | 2020-02-05 |
| A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | Migalastat | Phase 3 | Active, not recruiting | Amicus Therapeutics | 2019-07-15 |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Fabry disease
- 0.89
- Cardiomyopathy
- 0.60
- Abnormality of the cardiovascular system
- 0.56
- Kidney failure
- 0.47
- Familial hypertrophic cardiomyopathy
- 0.44
- Stroke disorder
- 0.37
- Ischemic stroke
- 0.37
- Cerebral small vessel disease
- 0.37
- Cystic kidney disease
- 0.37
- Hemorrhagic stroke
- 0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2524, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P06280, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets